← back to search

Karin Havenith

e-Therapeutics (United Kingdom) · GB
Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, and CAR-T cell therapy research.
h-index
14
citations
1,279
works
84
NIH funding
primary concept
Medicine
email

Recent publications

Abstract CT059: Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas
Cancer Research 2024cited by 6position: middledoi
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
Regular and Young Investigator Award Abstracts 2023cited by 3position: middledoi
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology 2021cited by 412position: middledoi
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Blood 2020cited by 168position: middledoi
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Blood Advances 2020cited by 56position: middledoi
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
Leukemia Research 2020cited by 41position: middledoi
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Clinical Cancer Research 2019cited by 106position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jay Feingold · Tagworks Pharmaceuticals (Netherlands)5 papers (2019–2021)Melhem Solh · University College London4 papers (2019–2021)Joseph Boni · Adc Therapeutics (Switzerland)4 papers (2019–2023)David Ungar · Adc Therapeutics (Switzerland)4 papers (2019–2021)Brad S. Kahl · New York University3 papers (2019–2021)Yajuan Qin · PTC Therapeutics (United States)3 papers (2020–2021)Mehdi Hamadani · Medical College of Wisconsin3 papers (2019–2021)John Radford · University of Manchester3 papers (2019–2021)Paolo F. Caimi · Cleveland Clinic3 papers (2019–2021)Carmelo Carlo‐Stella · Humanitas University3 papers (2019–2021)Kirit M. Ardeshna · University College Hospital3 papers (2019–2021)Leonard T. Heffner · Winship Cancer Institute3 papers (2019–2020)Ehab Atallah · Al-Azhar University2 papers (2020–2020) · 2 papers (2023–2024)Xiaoyan Zhang · Qingdao Agricultural University2 papers (2020–2021)Shui He · Guiyang Medical University2 papers (2019–2021) · 2 papers (2020–2020)Owen A. O’Connor · Virginia Cancer Institute2 papers (2019–2020)Christopher T. Chen · Cancer Prevention Institute of California2 papers (2023–2024)Wendy Stock · Leukemia Research Foundation2 papers (2020–2020)